R&D channel feed – Endpoints News

R&D channel feed

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

3 months ago

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

3 months ago

AstraZeneca wins BTK race to market in first-line mantle cell lymphoma

3 months ago

Broad Institute paper offers potential new framework for treating Huntington’s disease

3 months ago

Oncology biotech plots expedited approval for bone cancer drug after Phase 2 win

3 months ago

Anavex reports long-term Alzheimer's data for drug with history of scrutiny

3 months ago

Daiichi Sankyo brings Glycotope antibody in-house for $132.5M

3 months ago

Biohaven’s protein degrader is promising in early IgAN trial, heads straight to Phase 3

3 months ago

AbbVie partners with Simcere Pharma unit to develop myeloma drug

3 months ago

Hengrui and Kailera’s injected incretin posts best-in-class obesity data in Phase 2 trial

3 months ago

Gilead taps into STAT6 space via $250M deal with Leo Pharma

4 months ago

Regor’s obesity pill posts muted weight loss in Phase 2a, enters new trial

4 months ago

Bayer’s BlueRock now plans to bring Parkinson’s cell therapy straight to Phase 3 trial

4 months ago

Pfizer touts bladder cancer results as first advancement for some patients 'in decades'

4 months ago

Dyne details pivotal plans for myotonic dystrophy RNA drug, though data blip worries some investors

4 months ago

Repare pauses late-stage plans, reshuffles pipeline in effort to cut costs

4 months ago

Marea reports early Phase 2 data for cholesterol-lowering drug it licensed from Novartis

4 months ago

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

4 months ago

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment

4 months ago

Tenpoint reveals positive Phase 3 data for vision drug after Visus merger

4 months ago

Aiolos team reunites with $411M for new biotech with obesity drugs from China

4 months ago

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

4 months ago

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

4 months ago

Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request

4 months ago

First page Previous page 9 10 111213 14 15 Next page Last page